Press & Events
AVEO Pharmaceuticals to Present at IBC’s New Frontiers in Cancer Drug Development Conference
OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration
AVEO Pharmaceuticals Granted Patent for Predictive Biomarker Used to Identify Human Tumors Likely to Respond to Notch Pathway Inhibition
Aveo Kidney Cancer Drug, Challenging Pfizer and Bayer, Passes Important Test
AVEO Initiates Phase 1b/2a Clinical Trial of Novel, Triple VEGF Receptor Inhibitor AV-951 in Non-Small Cell Lung Cancer
AVEO Pharmaceuticals to Present at the Barclays Global Healthcare Conference
AVEO Pharmaceuticals’ Oral, Triple VEGF Receptor Inhibitor AV-951 Shows Robust Activity in Patients with Advanced Kidney Cancer
AVEO Pharmaceuticals Announces Oral Presentation of Data from AV-951 Phase 2 Clinical Trial at the 2009 Genitourinary Symposium
AVEO Pharmaceuticals to Present at 27th Annual J.P. Morgan Healthcare Conference
Dyax Corp. and AVEO Pharmaceuticals Announce Antibody Library License Agreement
Archived Press
2013
MayApril
March
February
January
2012
DecemberNovember
October
September
August
July
June
May
April
March
February
January